Skip to main content
Erschienen in: Current Allergy and Asthma Reports 6/2015

01.06.2015 | Allergic Skin Diseases (L Fonacier, Section Editor)

Urticaria Guidelines: Consensus and Controversies in the European and American Guidelines

verfasst von: Lauren M. Fine, Jonathan A. Bernstein

Erschienen in: Current Allergy and Asthma Reports | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Urticaria can present acutely and be self-limiting or become chronic and persist for weeks, months, or years. In either case, the condition may have a significant impact on the patient’s quality of life. Two major consensus groups, the EAACI/WAO and the AAAAI/ACAAI Joint Task Force, have written guidelines on the diagnosis and management of urticaria. While both agree on most points regarding the definition, general evaluation, and treatment, there are some differences which exist. The guidelines, which are written to assist both primary practitioners and specialists in managing their patients with urticaria, have been developed based on scientific evidence, and when insufficient evidence is available, then recommendations are based on expert consensus opinion. The majority of the differences between the two guidelines pertain to recommendations based on expert opinion because of weak scientific evidence. Within this document, we compare the recommendations of these two groups, highlighting the key similarities and differences.
Literatur
1.••
Zurück zum Zitat Zuberbier T, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, Church MK, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69:868–87. This is the document outlining the European guidelines for urticaria.PubMedCrossRef Zuberbier T, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, Church MK, et al. The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy. 2014;69:868–87. This is the document outlining the European guidelines for urticaria.PubMedCrossRef
2.••
Zurück zum Zitat Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol US Am Acad Allergy Asthma Immunol. 2014;133:1270–7. Published by Mosby, Inc. This is the document outlining the American guidelines for urticaria. Bernstein JA, Lang DM, Khan DA, Craig T, Dreyfus D, Hsieh F, et al. The diagnosis and management of acute and chronic urticaria: 2014 update. J Allergy Clin Immunol US Am Acad Allergy Asthma Immunol. 2014;133:1270–7. Published by Mosby, Inc. This is the document outlining the American guidelines for urticaria.
3.
Zurück zum Zitat Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau A, et al. EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy Eur J Allergy Clin Immunol. 2009;64:1417–26.CrossRef Zuberbier T, Asero R, Bindslev-Jensen C, Walter Canonica G, Church MK, Giménez-Arnau A, et al. EAACI/GA2LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy Eur J Allergy Clin Immunol. 2009;64:1417–26.CrossRef
4.
Zurück zum Zitat Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. Methods report on the development of the 2013 revision and update of the EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2014;69:e1–e29.PubMedCrossRef Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW, et al. Methods report on the development of the 2013 revision and update of the EAACI/GA(2) LEN/EDF/WAO guideline for the definition, classification, diagnosis, and management of urticaria. Allergy. 2014;69:e1–e29.PubMedCrossRef
5.
Zurück zum Zitat Shocket AL. Chronic urticaria: pathophysiology and etiology, or the what and why. Allergy Asthma Proc. 2006;27:90–5. Shocket AL. Chronic urticaria: pathophysiology and etiology, or the what and why. Allergy Asthma Proc. 2006;27:90–5.
6.
Zurück zum Zitat Confino-Cohen R, Chodick G, Shalev V, Leshno M, Kimhi O, Goldberg A. Chronic urticaria and autoimmunity: associations found in a large population study. J Allergy Clin. 2012;129:1307–13. ImmunolAllergy Clin Immunol Unit, Meir Medical Center, Kfar Saba, Israel. ronitco@clalit.org.il: American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc.CrossRef Confino-Cohen R, Chodick G, Shalev V, Leshno M, Kimhi O, Goldberg A. Chronic urticaria and autoimmunity: associations found in a large population study. J Allergy Clin. 2012;129:1307–13. ImmunolAllergy Clin Immunol Unit, Meir Medical Center, Kfar Saba, Israel. ronitco@clalit.org.il: American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc.CrossRef
7.
Zurück zum Zitat Powell RJ, Du Toit GL, Siddique N, Leech SC, Dixon TA, Clark AT, et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy. 2007;37:631–50. Clinical Immunology Unit, Queen’s Medical Centre, Nottingham, UK.PubMedCrossRef Powell RJ, Du Toit GL, Siddique N, Leech SC, Dixon TA, Clark AT, et al. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy. 2007;37:631–50. Clinical Immunology Unit, Queen’s Medical Centre, Nottingham, UK.PubMedCrossRef
8.
Zurück zum Zitat Ap K. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol. 2004;114:465–74.CrossRef Ap K. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol. 2004;114:465–74.CrossRef
9.
Zurück zum Zitat Chansakulporn S, Pongpreuksa S, Sangacharoenkit P, Pacharn P, Visitsunthorn N, Vichyanond P, et al. The natural history of chronic urticaria in childhood: a prospective study. J Am Acad Dermatol. 2014;71:663–8. The natural history of chronic urticaria in childhood: a prospective study. Division of Allergy and Immunology, Department of Pediatrics, Srinakarinwirot University, Bangkok, Thailand; Division of Allergy and Immunology, Department of Pediatrics, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Division of All (TRUNCATED: American Academy of Dermatology, Inc. Published by Elsevier Inc.PubMedCrossRef Chansakulporn S, Pongpreuksa S, Sangacharoenkit P, Pacharn P, Visitsunthorn N, Vichyanond P, et al. The natural history of chronic urticaria in childhood: a prospective study. J Am Acad Dermatol. 2014;71:663–8. The natural history of chronic urticaria in childhood: a prospective study. Division of Allergy and Immunology, Department of Pediatrics, Srinakarinwirot University, Bangkok, Thailand; Division of Allergy and Immunology, Department of Pediatrics, Siriraj Hospital, Mahidol University, Bangkok, Thailand; Division of All (TRUNCATED: American Academy of Dermatology, Inc. Published by Elsevier Inc.PubMedCrossRef
10.
Zurück zum Zitat Volonakis M, Katsarou-Katsari A, Stratigos J. Etiologic factors in childhood chronic urticaria. Ann Allergy. 1992;69:61–5.PubMed Volonakis M, Katsarou-Katsari A, Stratigos J. Etiologic factors in childhood chronic urticaria. Ann Allergy. 1992;69:61–5.PubMed
11.
Zurück zum Zitat Kauppinen K, Juntunen K, Lanki H. Urticaria in children. Retrospective evaluation and follow-up. Allergy. 1984;39:469–72.PubMedCrossRef Kauppinen K, Juntunen K, Lanki H. Urticaria in children. Retrospective evaluation and follow-up. Allergy. 1984;39:469–72.PubMedCrossRef
12.
Zurück zum Zitat Greenberger PA. Chronic urticaria: new management options. World Allergy Organ J. 2014;7:31–4551 – 7–31. eCollection 2014. Division of Allergy-Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, 676 N. St. Clair Street, # 14108, 60611 Chicago, IL USA. Greenberger PA. Chronic urticaria: new management options. World Allergy Organ J. 2014;7:31–4551 – 7–31. eCollection 2014. Division of Allergy-Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, 676 N. St. Clair Street, # 14108, 60611 Chicago, IL USA.
13.
Zurück zum Zitat Erbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol. 2002;110:484–8. Department of Dermatology, Gaziantep University Medical Faculty, Turkey.PubMedCrossRef Erbagci Z. The leukotriene receptor antagonist montelukast in the treatment of chronic idiopathic urticaria: a single-blind, placebo-controlled, crossover clinical study. J Allergy Clin Immunol. 2002;110:484–8. Department of Dermatology, Gaziantep University Medical Faculty, Turkey.PubMedCrossRef
14.
Zurück zum Zitat Grattan CE, O’Donnell BF, Francis DM, Niimi N, Barlow RJ, Seed PT, et al. Randomized double-blind study of cyclosporin in chronic “idiopathic” urticaria. Br J Dermatol. 2000;143:365–72. Dermatology Centre, West Norwich Hospital, Norwich NR2 3TU, UK. clive.grattan@norfolk-norwich.thenhs.com.PubMedCrossRef Grattan CE, O’Donnell BF, Francis DM, Niimi N, Barlow RJ, Seed PT, et al. Randomized double-blind study of cyclosporin in chronic “idiopathic” urticaria. Br J Dermatol. 2000;143:365–72. Dermatology Centre, West Norwich Hospital, Norwich NR2 3TU, UK. clive.grattan@norfolk-norwich.thenhs.com.PubMedCrossRef
15.
Zurück zum Zitat Mlynek A, Zalewska-Janowska A, Martus P, Staubach P, Zuberbier T, Maurer M. How to assess disease activity in patients with chronic urticaria? Allergy. 2008;63:777–80. Department of Dermatology and Allergy, Charite-Universitatsmedizin Berlin, Berlin, Germany.PubMedCrossRef Mlynek A, Zalewska-Janowska A, Martus P, Staubach P, Zuberbier T, Maurer M. How to assess disease activity in patients with chronic urticaria? Allergy. 2008;63:777–80. Department of Dermatology and Allergy, Charite-Universitatsmedizin Berlin, Berlin, Germany.PubMedCrossRef
16.
Zurück zum Zitat Baiardini I, Pasquali M, Braido F, Fumagalli F, Guerra L, Compalati E, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy. 2005;60:1073–8.PubMedCrossRef Baiardini I, Pasquali M, Braido F, Fumagalli F, Guerra L, Compalati E, et al. A new tool to evaluate the impact of chronic urticaria on quality of life: chronic urticaria quality of life questionnaire (CU-QoL). Allergy. 2005;60:1073–8.PubMedCrossRef
17.
Zurück zum Zitat Mathias SD, Crosby RD, Zazzali JL, Maurer M, Saini SS. Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2012;108:20–4.PubMedCrossRef Mathias SD, Crosby RD, Zazzali JL, Maurer M, Saini SS. Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria. Ann Allergy Asthma Immunol. 2012;108:20–4.PubMedCrossRef
18.
Zurück zum Zitat Saini S, Rosen KE, Hsieh HJ, Wong DA, Conner E, Kaplan A, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128:567–73.e1. Johns Hopkins Asthma and Allergy Center, Baltimore, MD 21224, USA. ssaini@jhmi.edu: American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc.PubMedCrossRef Saini S, Rosen KE, Hsieh HJ, Wong DA, Conner E, Kaplan A, et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J Allergy Clin Immunol. 2011;128:567–73.e1. Johns Hopkins Asthma and Allergy Center, Baltimore, MD 21224, USA. ssaini@jhmi.edu: American Academy of Allergy, Asthma & Immunology. Published by Mosby, Inc.PubMedCrossRef
19.
Zurück zum Zitat Młynek A, Magerl M, Hanna M, Lhachimi S, Baiardini I, Canonica GW, et al. The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings. Allergy. 2009;64:927–36.PubMedCrossRef Młynek A, Magerl M, Hanna M, Lhachimi S, Baiardini I, Canonica GW, et al. The German version of the Chronic Urticaria Quality-of-Life Questionnaire: factor analysis, validation, and initial clinical findings. Allergy. 2009;64:927–36.PubMedCrossRef
20.
Zurück zum Zitat Valero A, Herdman M, Bartra J, Ferrer M, Jáuregui I, Dávila I, et al. Adaptation and validation of the Spanish version of the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL). J Investig Allergol Clin Immunol [Internet]. 2008;18:426–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19123433. Valero A, Herdman M, Bartra J, Ferrer M, Jáuregui I, Dávila I, et al. Adaptation and validation of the Spanish version of the Chronic Urticaria Quality of Life Questionnaire (CU-Q2oL). J Investig Allergol Clin Immunol [Internet]. 2008;18:426–32. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​19123433.
21.
Zurück zum Zitat Platzer MH, Grattan CEH, Poulsen LK, Skov PS. Validation of basophil histamine release against the autologous serum skin test and outcome of serum-induced basophil histamine release studies in a large population of chronic urticaria patients. Allergy Eur J Allergy Clin Immunol. 2005;60:1152–6.CrossRef Platzer MH, Grattan CEH, Poulsen LK, Skov PS. Validation of basophil histamine release against the autologous serum skin test and outcome of serum-induced basophil histamine release studies in a large population of chronic urticaria patients. Allergy Eur J Allergy Clin Immunol. 2005;60:1152–6.CrossRef
22.
Zurück zum Zitat Konstantinou GN, Asero R, Maurer M, Sabroe RA, Schmid-Grendelmeier P, Grattan CE. EAACI/GA(2)LEN task force consensus report: the autologous serum skin test in urticaria. Allergy. 2009;64:1256–68. Allergy and Clinical Immunology Department, NIMTS, Army Hospital and Allergy Research Center National & Kapodistrian University of Athens, Greece.PubMedCrossRef Konstantinou GN, Asero R, Maurer M, Sabroe RA, Schmid-Grendelmeier P, Grattan CE. EAACI/GA(2)LEN task force consensus report: the autologous serum skin test in urticaria. Allergy. 2009;64:1256–68. Allergy and Clinical Immunology Department, NIMTS, Army Hospital and Allergy Research Center National & Kapodistrian University of Athens, Greece.PubMedCrossRef
23.
Zurück zum Zitat Maurer M, Weller K, Bindslev-Jensen C, Gimenez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report. Allergy. 2011;66:317–30. Department of Dermatology and Allergy, Charite- Universitatsmedizin Berlin, Berlin, Germany. marcus.maurer@charite.de: John Wiley & Sons A/S.PubMedCrossRef Maurer M, Weller K, Bindslev-Jensen C, Gimenez-Arnau A, Bousquet PJ, Bousquet J, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA(2)LEN task force report. Allergy. 2011;66:317–30. Department of Dermatology and Allergy, Charite- Universitatsmedizin Berlin, Berlin, Germany. marcus.maurer@charite.de: John Wiley & Sons A/S.PubMedCrossRef
24.
Zurück zum Zitat Quaranta JH, Rohr AS, Rachelefsky GS, Siegel SC, Katz RM, Spector SL, et al. The natural history and response to therapy of chronic urticaria and angioedema. Ann Allergy. 1989;62:421–4. United States.PubMed Quaranta JH, Rohr AS, Rachelefsky GS, Siegel SC, Katz RM, Spector SL, et al. The natural history and response to therapy of chronic urticaria and angioedema. Ann Allergy. 1989;62:421–4. United States.PubMed
25.
Zurück zum Zitat Kozel MM, Mekkes JR, Bossuyt PM, Bos JD. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol. 2001;45:387–91. Department of Dermatology, Academic Medical Center, University of Amsterdam, The Netherlands.PubMedCrossRef Kozel MM, Mekkes JR, Bossuyt PM, Bos JD. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol. 2001;45:387–91. Department of Dermatology, Academic Medical Center, University of Amsterdam, The Netherlands.PubMedCrossRef
26.
Zurück zum Zitat Amin P, Levin L, Holmes SJ, Picard J, Bernstein JA. Investigation of patient-specific characteristics associated with treatment outcomes for chronic urticaria. J Allergy Clin Immunol Pr. 2015. doi:10.1016/j.jaip.2014.12.007. Amin P, Levin L, Holmes SJ, Picard J, Bernstein JA. Investigation of patient-specific characteristics associated with treatment outcomes for chronic urticaria. J Allergy Clin Immunol Pr. 2015. doi:10.​1016/​j.​jaip.​2014.​12.​007.
27.
Zurück zum Zitat Ring J, Hein R, Gauger A, Bronsky E, Miller B. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol [Internet]. 2001;40:72–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11277962\nhttp://apps.isiknowledge.com/full_record.do?product=UA&search_mode=GeneralSearch&qid=8&SID=T2FFQ4fEGczccZ8jE6Z&page=9&doc=419. Ring J, Hein R, Gauger A, Bronsky E, Miller B. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol [Internet]. 2001;40:72–6. Available from: http://​www.​ncbi.​nlm.​nih.​gov/​pubmed/​11277962\nhttp://apps.isiknowledge.com/full_record.do?product=UA&search_mode=GeneralSearch&qid=8&SID=T2FFQ4fEGczccZ8jE6Z&page=9&doc=419.
28.•
Zurück zum Zitat Staevska M, Popov TA, Kralimarkova T, Lazarova C, Kraeva S, Popova D, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010;125:676–82. Evidence supporting step 2 of both the JTF and EAACI guidelines to increase 2nd generation antihistamines up to 4 times the conventional dose. This is generally very effective, safe and easy to manage for many patients.PubMedCrossRef Staevska M, Popov TA, Kralimarkova T, Lazarova C, Kraeva S, Popova D, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-to-treat urticaria. J Allergy Clin Immunol. 2010;125:676–82. Evidence supporting step 2 of both the JTF and EAACI guidelines to increase 2nd generation antihistamines up to 4 times the conventional dose. This is generally very effective, safe and easy to manage for many patients.PubMedCrossRef
29.
Zurück zum Zitat Nettis E, Dambra P, D’Oronzio L, Loria MP, Ferrannini A, Tursi A. Comparison of montelukast and fexofenadine for chronic idiopathic urticaria. Arch Dermatol. 2001;137:99–100. United States.PubMed Nettis E, Dambra P, D’Oronzio L, Loria MP, Ferrannini A, Tursi A. Comparison of montelukast and fexofenadine for chronic idiopathic urticaria. Arch Dermatol. 2001;137:99–100. United States.PubMed
30.
Zurück zum Zitat Sanada S, Tanaka T, Kameyoshi Y, Hide M. The effectiveness of montelukast for the treatment of anti-histamine-resistant chronic urticaria. Arch Dermatol Res. 2005;297:134–8. Department of Dermatology, Programs for Biomedical Research, Division of Molecular Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima 734-8551, Japan.PubMedCrossRef Sanada S, Tanaka T, Kameyoshi Y, Hide M. The effectiveness of montelukast for the treatment of anti-histamine-resistant chronic urticaria. Arch Dermatol Res. 2005;297:134–8. Department of Dermatology, Programs for Biomedical Research, Division of Molecular Medical Science, Graduate School of Biomedical Sciences, Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima 734-8551, Japan.PubMedCrossRef
31.
Zurück zum Zitat Nettis E, Colanardi MC, Paradiso MT, Ferrannini A. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy. 2004;34:1401–7. Department of Medical Clinic, Immunology and Infectious Diseases, Section of Allergy and Clinical Immunology, University of Bari, Bari, Italy. e.nettis@allergy.uniba.it.PubMedCrossRef Nettis E, Colanardi MC, Paradiso MT, Ferrannini A. Desloratadine in combination with montelukast in the treatment of chronic urticaria: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy. 2004;34:1401–7. Department of Medical Clinic, Immunology and Infectious Diseases, Section of Allergy and Clinical Immunology, University of Bari, Bari, Italy. e.nettis@allergy.uniba.it.PubMedCrossRef
32.
Zurück zum Zitat Bagenstose SE, Levin L, Bernstein JA. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J Allergy Clin Immunol. 2004;113:134–40.PubMedCrossRef Bagenstose SE, Levin L, Bernstein JA. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J Allergy Clin Immunol. 2004;113:134–40.PubMedCrossRef
33.
Zurück zum Zitat Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, et al. Humanization of an antibody directed against IgE. J Immunol. 1993;151:2623–32.PubMed Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, et al. Humanization of an antibody directed against IgE. J Immunol. 1993;151:2623–32.PubMed
34.•
Zurück zum Zitat Maurer M, Rosen K, Hsieh HJ, Saini S, Grattan C, Gimenez-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924–35. Highlights the most efficacious dose of omalizumab (300 mg SC every 4 weeks) and the use of the UAS7 score to quantify response to treatment. Department of Dermatology and Allergy, Charite-Universitatsmedizin, Berlin.PubMedCrossRef Maurer M, Rosen K, Hsieh HJ, Saini S, Grattan C, Gimenez-Arnau A, et al. Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. N Engl J Med. 2013;368:924–35. Highlights the most efficacious dose of omalizumab (300 mg SC every 4 weeks) and the use of the UAS7 score to quantify response to treatment. Department of Dermatology and Allergy, Charite-Universitatsmedizin, Berlin.PubMedCrossRef
35.
Zurück zum Zitat Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med. 2006;354:2689–95. Department of Pediatrics, Washington University School of Medicine, St. Louis, USA.PubMedCrossRef Strunk RC, Bloomberg GR. Omalizumab for asthma. N Engl J Med. 2006;354:2689–95. Department of Pediatrics, Washington University School of Medicine, St. Louis, USA.PubMedCrossRef
36.
Zurück zum Zitat Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy. 2009;39:788–97. Allergy Research Foundation, Los Angeles, CA 90025, USA. jcorren@ucla.edu.PubMedCrossRef Corren J, Casale TB, Lanier B, Buhl R, Holgate S, Jimenez P. Safety and tolerability of omalizumab. Clin Exp Allergy. 2009;39:788–97. Allergy Research Foundation, Los Angeles, CA 90025, USA. jcorren@ucla.edu.PubMedCrossRef
37.
Zurück zum Zitat Chiang DT, Clark J, Casale TB. Omalizumab in asthma: approval and postapproval experience. Clin Rev Allergy Immunol. 2005;29:3–16. Division of Allergy and Immunology, Creighton University Medical Center, Omaha, NE, USA.PubMedCrossRef Chiang DT, Clark J, Casale TB. Omalizumab in asthma: approval and postapproval experience. Clin Rev Allergy Immunol. 2005;29:3–16. Division of Allergy and Immunology, Creighton University Medical Center, Omaha, NE, USA.PubMedCrossRef
Metadaten
Titel
Urticaria Guidelines: Consensus and Controversies in the European and American Guidelines
verfasst von
Lauren M. Fine
Jonathan A. Bernstein
Publikationsdatum
01.06.2015
Verlag
Springer US
Erschienen in
Current Allergy and Asthma Reports / Ausgabe 6/2015
Print ISSN: 1529-7322
Elektronische ISSN: 1534-6315
DOI
https://doi.org/10.1007/s11882-015-0535-z

Weitere Artikel der Ausgabe 6/2015

Current Allergy and Asthma Reports 6/2015 Zur Ausgabe

Asthma (WJ Calhoun and S Peters, Section Editors)

Asthma is Different in Women

Anaphylaxis and Drug Allergy (DA Khan and M Castells, Section Editors)

Utility of Component-Resolved Diagnostics in Food Allergy

Rhinosinusitis (J Mullol, Section Editor)

Remodeling and Repair in Rhinosinusitis

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

HNO-Op. auch mit über 90?

16.04.2024 HNO-Chirurgie Nachrichten

Mit Blick auf das Risiko für Komplikationen nach elektiven Eingriffen im HNO-Bereich scheint das Alter der Patienten kein ausschlaggebender Faktor zu sein. Entscheidend ist offenbar, wie fit die Betroffenen tatsächlich sind.

Intrakapsuläre Tonsillektomie gewinnt an Boden

16.04.2024 Tonsillektomie Nachrichten

Gegenüber der vollständigen Entfernung der Gaumenmandeln hat die intrakapsuläre Tonsillektomie einige Vorteile, wie HNO-Fachleute aus den USA hervorheben. Sie haben die aktuelle Literatur zu dem Verfahren gesichtet.

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.